EDIT

Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends

01/22 05:56 am

Gene Therapies for Cancer Treatment Market Projects USD 238.77 Billion at 39.94% CAGR by 2034

11/17 11:00 am

Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus

09/25 09:15 am

Gene Editing Market to Surpass USD 15.46 Billion by 2032, Fueled by Breakthroughs in CRISPR Technology and Precision Medicine – SNS Insider

09/02 06:00 am

2 Beaten-Down Stocks to Avoid

06/27 08:15 am

Editas Medicine Is Great. Here's Why You Shouldn't Buy It.

06/17 10:07 am

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

06/12 02:01 am

Global Genome Editing Market to Grow Rapidly at a CAGR ~13% by 2032 | DelveInsight

03/06 02:00 pm

Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight

02/21 02:00 pm

Gene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147%

09/10 04:51 am

Gene Therapy Market Size to Reach USD 54.39 Billion By 2032 with CAGR of 23.12%, Boosted by Rising Genetic Disorders and Advances in CRISPR Technology

08/30 08:59 am

Editas Medicine to Participate in Upcoming Investor Conferences

08/28 09:00 am

Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies

06/17 08:13 am

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

06/14 03:01 am

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress

06/14 03:00 am

Editas (EDIT) Down 2.3% Since Last Earnings Report: Can It Rebound?

06/07 11:30 am

The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts

05/30 12:00 pm

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June

05/14 10:00 am

Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting

05/10 06:00 am

1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?

05/09 01:12 pm

Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down

05/09 12:40 pm

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

05/08 08:25 am

Wall Street Breakfast: The Week Ahead

05/05 06:27 am

The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine

05/03 05:08 am

Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More

05/02 10:02 am

Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events

05/02 07:00 am

Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know

04/26 10:00 am

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

04/22 04:31 pm

Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report?

03/29 11:30 am

1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.

03/07 04:31 am

1 Beaten-Down Stock With 55% Upside, According to Wall Street

03/04 11:30 am

Why Editas Medicine Stock Soared as Much as 42% Higher This Week

03/02 10:49 pm

The Latest Analyst Ratings For Editas Medicine

02/29 01:00 pm

Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up

02/29 09:42 am

Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

02/28 03:02 pm

Advance Auto Parts Reports Q4 Results, Joins B&G Foods, Vipshop, ADT And Other Big Stocks Moving Higher On Wednesday

02/28 12:37 pm

Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates

02/28 09:10 am

Krystal Biotech, Inc. (KRYS) Tops Q4 Earnings and Revenue Estimates

02/26 10:25 am

Bausch (BHC) Q4 Earnings and Revenues Top Estimates

02/23 12:53 pm

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events

02/21 08:00 am

Bayer (BAYRY) Intends to Slash Dividends Amid Challenges

02/20 09:50 am

Wall Street Analysts Believe Editas (EDIT) Could Rally 80%: Here's is How to Trade

02/19 10:55 am

Vertex (VRTX), CRSP's Casgevy Gets EU Nod for Two Blood Disorders

02/14 08:32 am

Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology

02/14 07:00 am

5 Biotech Stocks to Consider for Your Portfolio in 2024

02/13 10:00 am

What Makes Editas (EDIT) a New Buy Stock

02/06 01:00 pm

2 Under-the-Radar Stocks With Incredible Upside Potential

01/28 09:45 am

Could Editas Medicine Become the Next CRISPR Therapeutics?

01/21 10:37 am

Down 88%, Could Editas Medicine Be a Good Investment Now?

01/15 06:19 am

Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference

01/08 09:15 am